Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement

被引:18
作者
Kim, Moonsik [1 ]
Hwang, Jinha [2 ,3 ]
Kim, Kyung A. [4 ]
Hwang, Sohyun [5 ]
Lee, Hye-Jeong [6 ,7 ]
Jung, Ji Ye [8 ]
Lee, Jin Gu [9 ]
Cha, Yoon Jin [4 ]
Shim, Hyo Sup [4 ]
机构
[1] Kyungpook Natl Univ, Sch Med, Dept Pathol, Chilgok Hosp, Daegu, South Korea
[2] Macrogen Inc, Seoul, South Korea
[3] Korea Univ, Dept Lab Med, Anam Hosp, Seoul, South Korea
[4] Yonsei Univ, Dept Pathol, Coll Med, Seoul, South Korea
[5] CHA Univ, Dept Pathol, Sch Med, Seongnam, South Korea
[6] Yonsei Univ, Severance Hosp, Dept Radiol, Coll Med, Seoul, South Korea
[7] Yonsei Univ, Severance Hosp, Res Inst Radiol Sci, Coll Med, Seoul, South Korea
[8] Yonsei Univ, Severance Hosp, Dept Internal Med, Div Pulmonol,Coll Med, Seoul, South Korea
[9] Yonsei Univ, Severance Hosp, Dept Thorac & Cardiovasc Surg, Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
TUMOR MUTATIONAL BURDEN; FUSION GENE; CANCER; HETEROGENEITY; KRAS; CLASSIFICATION; IMMUNOTHERAPY; INSTABILITY; ALIGNMENT; PROGRAM;
D O I
10.1038/s41379-021-00872-0
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Invasive mucinous adenocarcinoma (IMA) of the lung frequently presents with diffuse pneumonic-type features or multifocal lesions, which are regarded as a pattern of intrapulmonary metastases. However, the genomics of multifocal IMAs have not been well studied. We performed whole exome sequencing on samples taken from 2 to 5 regions in seven patients with synchronous multifocal IMAs of the lung (24 regions total). Early initiating driver events, such as KRAS, NKX2-1, TP53, or ARID1A mutations, are clonal mutations and were present in all multifocal IMAs in each patient. The tumor mutational burden of multifocal IMAs was low (mean: 1.13/mega base), but further analyses suggested intra-tumor heterogeneity. The mutational signature analysis found that IMAs were predominantly associated with endogenous mutational process (signature 1), APOBEC activity (signatures 2 and 13), and defective DNA mismatch repair (signature 6), but not related to smoking signature. IMAs synchronously located in the bilateral lower lobes of two patients with background usual interstitial pneumonia had different mutation types, suggesting that they were double primaries. In conclusion, genomic evidence found in this study indicated the clonal intrapulmonary spread of diffuse pneumonic-type or multifocal IMAs, although they can occur in multicentric origins in the background of usual interstitial pneumonia. IMAs exhibited a heterogeneous genomic landscape despite the low somatic mutation burden. Further studies are warranted to determine the clinical significance of the genomic characteristics of IMAs in expanded cohorts.
引用
收藏
页码:202 / 209
页数:8
相关论文
共 59 条
  • [1] Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?
    Alexander, Mariam
    Galeas, Jose
    Cheng, Haiying
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 : S3994 - S3998
  • [2] Mutational signatures associated with tobacco smoking in human cancer
    Alexandrov, Ludmil B.
    Ju, Young Seok
    Haase, Kerstin
    Van Loo, Peter
    Martincorena, Inigo
    Nik-Zainal, Serena
    Totoki, Yasushi
    Fujimoto, Akihiro
    Nakagawa, Hidewaki
    Shibata, Tatsuhiro
    Campbell, Peter J.
    Vineis, Paolo
    Phillips, David H.
    Stratton, Michael R.
    [J]. SCIENCE, 2016, 354 (6312) : 618 - 622
  • [3] Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non-Small Cell Lung Cancer
    Arbour, Kathryn C.
    Jordan, Emmett
    Kim, Hyunjae Ryan
    Dienstag, Jordan
    Yu, Helena A.
    Sanchez-Vega, Francisco
    Lito, Piro
    Berger, Michael
    Solit, David B.
    Hellmann, Matthew
    Kris, Mark G.
    Rudin, Charles M.
    Ni, Ai
    Arcila, Maria
    Ladanyi, Marc
    Riely, Gregory J.
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (02) : 334 - 340
  • [4] AbsCN-seq: a statistical method to estimate tumor purity, ploidy and absolute copy numbers from next-generation sequencing data
    Bao, Lei
    Pu, Minya
    Messer, Karen
    [J]. BIOINFORMATICS, 2014, 30 (08) : 1056 - 1063
  • [5] Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
    Berland, Lea
    Heeke, Simon
    Humbert, Olivier
    Macocco, Adam
    Long-Mira, Elodie
    Lassalle, Sandra
    Lespinet-Fabre, Virginie
    Lalvee, Salome
    Bordone, Olivier
    Cohen, Charlotte
    Leroy, Sylvie
    Hofman, Veronique
    Hofman, Paul
    Ilie, Marius
    [J]. JOURNAL OF THORACIC DISEASE, 2019, 11 : S71 - S80
  • [6] Landscape of Microsatellite Instability Across 39 Cancer Types
    Bonneville, Russell
    Krook, Melanie A.
    Kautto, Esko A.
    Miya, Jharna
    Wing, Michele R.
    Chen, Hui-Zi
    Reeser, Julie W.
    Yu, Lianbo
    Roychowdhury, Sameek
    [J]. JCO PRECISION ONCOLOGY, 2017, 1 : 1 - 15
  • [7] Implementing TMB measurement in clinical practice: considerations on assay requirements
    Buettner, Reinhard
    Longshore, John W.
    Lopez-Rios, Fernando
    Merkelbach-Bruse, Sabine
    Normanno, Nicola
    Rouleau, Etienne
    Penault-Llorca, Frederique
    [J]. ESMO OPEN, 2019, 4 (01)
  • [8] The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
    Canon, Jude
    Rex, Karen
    Saiki, Anne Y.
    Mohr, Christopher
    Cooke, Keegan
    Bagal, Dhanashri
    Gaida, Kevin
    Holt, Tyler
    Knutson, Charles G.
    Koppada, Neelima
    Lanman, Brian A.
    Werner, Jonathan
    Rapaport, Aaron S.
    San Miguel, Tisha
    Ortiz, Roberto
    Osgood, Tao
    Sun, Ji-Rong
    Zhu, Xiaochun
    McCarter, John D.
    Volak, Laurie P.
    Houk, Brett E.
    Fakih, Marwan G.
    O'Neil, Bert H.
    Price, Timothy J.
    Falchook, Gerald S.
    Desai, Jayesh
    Kuo, James
    Govindan, Ramaswamy
    Hong, David S.
    Ouyang, Wenjun
    Henary, Haby
    Arvedson, Tara
    Cee, Victor J.
    Lipford, J. Russell
    [J]. NATURE, 2019, 575 (7781) : 217 - +
  • [9] Biology of invasive mucinous adenocarcinoma of the lung
    Cha, Yoon Jin
    Shim, Hyo Sup
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2017, 6 (05) : 508 - 512
  • [10] Clinical course of stage IV invasive mucinous adenocarcinoma of the lung
    Cha, Yoon Jin
    Kim, Hye Ryun
    Lee, Hye-Jeong
    Cho, Byoung Chul
    Shim, Hyo Sup
    [J]. LUNG CANCER, 2016, 102 : 82 - 88